Cayman
Showing 38701–38850 of 45550 results
-
Sanggenone C is a flavonoid that has been found in mulberry bark and has diverse biological activities.{48989,48990,48991,48992} It inhibits TNF-α- or IL-1β-induced polymorphonuclear leukocyte (PMN) adhesion to human synovial cells (HSCs; IC50s = 27.29 and 54.43 nM, respectively), as well as inhibits NF-κB activation in HSCs.{48989} Sanggenone C induces apoptosis and production of reactive oxygen species (ROS) in HT-29 cells when used at concentrations ranging from 10 to 40 µM.{48990} It decreases cell viability of HT-29 cells in vitro and reduces tumor growth in an HT-29 mouse xenograft model when administered at a dose of 10 mg/kg. Sanggenone C increases vertebrate column bone mineralization in a zebrafish model of prednisone-induced osteoporosis.{48991} It also attenuates cardiac hypertrophy and fibrosis and reduces activation of nuclear factor of activated T cells 2 (NFAT2) in a mouse model of pressure overload-induced cardiac hypertrophy.{48992}
Brand:CaymanSKU:30061 - 10 mgAvailable on backorder
Sanggenone C is a flavonoid that has been found in mulberry bark and has diverse biological activities.{48989,48990,48991,48992} It inhibits TNF-α- or IL-1β-induced polymorphonuclear leukocyte (PMN) adhesion to human synovial cells (HSCs; IC50s = 27.29 and 54.43 nM, respectively), as well as inhibits NF-κB activation in HSCs.{48989} Sanggenone C induces apoptosis and production of reactive oxygen species (ROS) in HT-29 cells when used at concentrations ranging from 10 to 40 µM.{48990} It decreases cell viability of HT-29 cells in vitro and reduces tumor growth in an HT-29 mouse xenograft model when administered at a dose of 10 mg/kg. Sanggenone C increases vertebrate column bone mineralization in a zebrafish model of prednisone-induced osteoporosis.{48991} It also attenuates cardiac hypertrophy and fibrosis and reduces activation of nuclear factor of activated T cells 2 (NFAT2) in a mouse model of pressure overload-induced cardiac hypertrophy.{48992}
Brand:CaymanSKU:30061 - 5 mgAvailable on backorder
Sanguinarine is a benzylisoquinoline alkaloid isolated from plants belonging to the family Papaveraceae.{22467} It exhibits antimicrobial, anti-inflammatory, and anti-oxidant properties and demonstrates antiproliferative and pro-apoptotic effects in some cancer cell lines. Sanguinarine suppresses NF-κB activation by blocking the degradation of IκBα and sensitizes cancer cells to apoptosis by inducing ROS generation and activating TNF-related apoptosis-inducing ligand.{25057} Furthermore, sanguinarine has been shown to reduce cancer cell metastasis though the inhibition of MMP-2 and MMP-9 activation and to exhibit antiangiogenic activity by downregulating VEGF-induced Akt activation.{25057}
Brand:CaymanSKU:-Out of stock
Sanguinarine is a benzylisoquinoline alkaloid isolated from plants belonging to the family Papaveraceae.{22467} It exhibits antimicrobial, anti-inflammatory, and anti-oxidant properties and demonstrates antiproliferative and pro-apoptotic effects in some cancer cell lines. Sanguinarine suppresses NF-κB activation by blocking the degradation of IκBα and sensitizes cancer cells to apoptosis by inducing ROS generation and activating TNF-related apoptosis-inducing ligand.{25057} Furthermore, sanguinarine has been shown to reduce cancer cell metastasis though the inhibition of MMP-2 and MMP-9 activation and to exhibit antiangiogenic activity by downregulating VEGF-induced Akt activation.{25057}
Brand:CaymanSKU:-Out of stock
Sanguinarine is a benzylisoquinoline alkaloid isolated from plants belonging to the family Papaveraceae.{22467} It exhibits antimicrobial, anti-inflammatory, and anti-oxidant properties and demonstrates antiproliferative and pro-apoptotic effects in some cancer cell lines. Sanguinarine suppresses NF-κB activation by blocking the degradation of IκBα and sensitizes cancer cells to apoptosis by inducing ROS generation and activating TNF-related apoptosis-inducing ligand.{25057} Furthermore, sanguinarine has been shown to reduce cancer cell metastasis though the inhibition of MMP-2 and MMP-9 activation and to exhibit antiangiogenic activity by downregulating VEGF-induced Akt activation.{25057}
Brand:CaymanSKU:-Out of stock
Sanguinarine is a benzylisoquinoline alkaloid isolated from plants belonging to the family Papaveraceae.{22467} It exhibits antimicrobial, anti-inflammatory, and anti-oxidant properties and demonstrates antiproliferative and pro-apoptotic effects in some cancer cell lines. Sanguinarine suppresses NF-κB activation by blocking the degradation of IκBα and sensitizes cancer cells to apoptosis by inducing ROS generation and activating TNF-related apoptosis-inducing ligand.{25057} Furthermore, sanguinarine has been shown to reduce cancer cell metastasis though the inhibition of MMP-2 and MMP-9 activation and to exhibit antiangiogenic activity by downregulating VEGF-induced Akt activation.{25057}
Brand:CaymanSKU:-Out of stock
Smoothened (SMO) is a GPCR-like receptor which, with Patched, mediates hedgehog signaling to regulate gene expression through the Gli transcription factors.{21774} SANT 1 is a potent inhibitor of hedgehog signaling that acts by directly antagonizing SMO (IC50 = 20 nM).{21771} It counteracts SMO activation by the SMO agonist SAG but only partially competes with SAG binding to SMO.{21771,24191} SANT 1 targets inactive SMO while it is in the cytoplasm, before it relocates to the primary cilium and is activated.{22122} Through antagonism of SMO, SANT 1 represses Gli-mediated transcription in a variety of cell types.{22122,24193}
Brand:CaymanSKU:- Smoothened (SMO) is a GPCR-like receptor which, with Patched, mediates hedgehog signaling to regulate gene expression through the Gli transcription factors.{21774} SANT 1 is a potent inhibitor of hedgehog signaling that acts by directly antagonizing SMO (IC50 = 20 nM).{21771} It counteracts SMO activation by the SMO agonist SAG but only partially competes with SAG binding to SMO.{21771,24191} SANT 1 targets inactive SMO while it is in the cytoplasm, before it relocates to the primary cilium and is activated.{22122} Through antagonism of SMO, SANT 1 represses Gli-mediated transcription in a variety of cell types.{22122,24193}
Brand:CaymanSKU:- Smoothened (SMO) is a GPCR-like receptor which, with Patched, mediates hedgehog signaling to regulate gene expression through the Gli transcription factors.{21774} SANT 1 is a potent inhibitor of hedgehog signaling that acts by directly antagonizing SMO (IC50 = 20 nM).{21771} It counteracts SMO activation by the SMO agonist SAG but only partially competes with SAG binding to SMO.{21771,24191} SANT 1 targets inactive SMO while it is in the cytoplasm, before it relocates to the primary cilium and is activated.{22122} Through antagonism of SMO, SANT 1 represses Gli-mediated transcription in a variety of cell types.{22122,24193}
Brand:CaymanSKU:-
SANT-2 is a Smoothened (Smo) receptor antagonist.{21771,24191} It binds to the Smo receptor (Kd = 12 nM) and inhibits binding of the Smo receptor agonist SAG-1.3 (SAG; Item No. 11914) and antagonist cyclopamine (Item No. 11321) (Kis = 7.8 and 8.4 nM, respectively). SANT-2 inhibits hedgehog signaling induced by an N-terminal fragment of sonic hedgehog (Shh) in an Shh-LIGHT2 cellular assay (IC50 = 30 nM).{21771}
Brand:CaymanSKU:21208 -Out of stock
SANT-2 is a Smoothened (Smo) receptor antagonist.{21771,24191} It binds to the Smo receptor (Kd = 12 nM) and inhibits binding of the Smo receptor agonist SAG-1.3 (SAG; Item No. 11914) and antagonist cyclopamine (Item No. 11321) (Kis = 7.8 and 8.4 nM, respectively). SANT-2 inhibits hedgehog signaling induced by an N-terminal fragment of sonic hedgehog (Shh) in an Shh-LIGHT2 cellular assay (IC50 = 30 nM).{21771}
Brand:CaymanSKU:21208 -Out of stock
SANT-2 is a Smoothened (Smo) receptor antagonist.{21771,24191} It binds to the Smo receptor (Kd = 12 nM) and inhibits binding of the Smo receptor agonist SAG-1.3 (SAG; Item No. 11914) and antagonist cyclopamine (Item No. 11321) (Kis = 7.8 and 8.4 nM, respectively). SANT-2 inhibits hedgehog signaling induced by an N-terminal fragment of sonic hedgehog (Shh) in an Shh-LIGHT2 cellular assay (IC50 = 30 nM).{21771}
Brand:CaymanSKU:21208 -Out of stock
SANT-2 is a Smoothened (Smo) receptor antagonist.{21771,24191} It binds to the Smo receptor (Kd = 12 nM) and inhibits binding of the Smo receptor agonist SAG-1.3 (SAG; Item No. 11914) and antagonist cyclopamine (Item No. 11321) (Kis = 7.8 and 8.4 nM, respectively). SANT-2 inhibits hedgehog signaling induced by an N-terminal fragment of sonic hedgehog (Shh) in an Shh-LIGHT2 cellular assay (IC50 = 30 nM).{21771}
Brand:CaymanSKU:21208 -Out of stock
Santonin is a sesquiterpenoid lactone that has been found in Artemisia.{48410} It has been used as a building block in the synthesis of terpenoids. Santonin is an anthelmintic that induces paralysis of A. lumbricoides.{48411}
Brand:CaymanSKU:27460 - 10 gAvailable on backorder
Santonin is a sesquiterpenoid lactone that has been found in Artemisia.{48410} It has been used as a building block in the synthesis of terpenoids. Santonin is an anthelmintic that induces paralysis of A. lumbricoides.{48411}
Brand:CaymanSKU:27460 - 5 gAvailable on backorder
Sappanone A is a homoisoflavonoid with diverse biological activities that has been isolated from the aerial parts of C. pulcherrima, the heartwood of C. sappan, and the stems of H. campechianum.{41699,41700,41701,41702,41703} In vitro, sappanone A inhibits 76.2, 59.2, 37.4, and 35.4% of FGFR1, KDR, c-Met, and c-Kit kinase activity, respectively, when used at a concentration of 10 μM.{41699} It also inhibits influenza viral neuraminidase (NA) with IC50 values of 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively.{41700} Sappanone A has antibacterial activity against Gram-positive B. subtilis, B. sphaericus, and S. aureus as well as Gram-negative K. aerogenes and C. violaceum.{41701} It also inhibits the growth of A. niger and C. albicans fungi. Sapannone A inhibits LPS-induced inflammatory responses in vitro and in vivo, reducing nitric oxide (NO), interleukin-6 (IL-6), and prostaglandin E2 (PGE2; Item No. 14010) production in RAW264.7 cells as well as LPS-induced mortality in mice.{41702} It also attenuates airway inflammation and mucus hypersecretion via activation of the Nrf2 signaling pathway in a mouse model of ovalbumin-induced asthma.{41703}
Brand:CaymanSKU:23205 - 10 mgAvailable on backorder
Sappanone A is a homoisoflavonoid with diverse biological activities that has been isolated from the aerial parts of C. pulcherrima, the heartwood of C. sappan, and the stems of H. campechianum.{41699,41700,41701,41702,41703} In vitro, sappanone A inhibits 76.2, 59.2, 37.4, and 35.4% of FGFR1, KDR, c-Met, and c-Kit kinase activity, respectively, when used at a concentration of 10 μM.{41699} It also inhibits influenza viral neuraminidase (NA) with IC50 values of 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively.{41700} Sappanone A has antibacterial activity against Gram-positive B. subtilis, B. sphaericus, and S. aureus as well as Gram-negative K. aerogenes and C. violaceum.{41701} It also inhibits the growth of A. niger and C. albicans fungi. Sapannone A inhibits LPS-induced inflammatory responses in vitro and in vivo, reducing nitric oxide (NO), interleukin-6 (IL-6), and prostaglandin E2 (PGE2; Item No. 14010) production in RAW264.7 cells as well as LPS-induced mortality in mice.{41702} It also attenuates airway inflammation and mucus hypersecretion via activation of the Nrf2 signaling pathway in a mouse model of ovalbumin-induced asthma.{41703}
Brand:CaymanSKU:23205 - 25 mgAvailable on backorder
Sappanone A is a homoisoflavonoid with diverse biological activities that has been isolated from the aerial parts of C. pulcherrima, the heartwood of C. sappan, and the stems of H. campechianum.{41699,41700,41701,41702,41703} In vitro, sappanone A inhibits 76.2, 59.2, 37.4, and 35.4% of FGFR1, KDR, c-Met, and c-Kit kinase activity, respectively, when used at a concentration of 10 μM.{41699} It also inhibits influenza viral neuraminidase (NA) with IC50 values of 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively.{41700} Sappanone A has antibacterial activity against Gram-positive B. subtilis, B. sphaericus, and S. aureus as well as Gram-negative K. aerogenes and C. violaceum.{41701} It also inhibits the growth of A. niger and C. albicans fungi. Sapannone A inhibits LPS-induced inflammatory responses in vitro and in vivo, reducing nitric oxide (NO), interleukin-6 (IL-6), and prostaglandin E2 (PGE2; Item No. 14010) production in RAW264.7 cells as well as LPS-induced mortality in mice.{41702} It also attenuates airway inflammation and mucus hypersecretion via activation of the Nrf2 signaling pathway in a mouse model of ovalbumin-induced asthma.{41703}
Brand:CaymanSKU:23205 - 5 mgAvailable on backorder
Sappanone A is a homoisoflavonoid with diverse biological activities that has been isolated from the aerial parts of C. pulcherrima, the heartwood of C. sappan, and the stems of H. campechianum.{41699,41700,41701,41702,41703} In vitro, sappanone A inhibits 76.2, 59.2, 37.4, and 35.4% of FGFR1, KDR, c-Met, and c-Kit kinase activity, respectively, when used at a concentration of 10 μM.{41699} It also inhibits influenza viral neuraminidase (NA) with IC50 values of 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively.{41700} Sappanone A has antibacterial activity against Gram-positive B. subtilis, B. sphaericus, and S. aureus as well as Gram-negative K. aerogenes and C. violaceum.{41701} It also inhibits the growth of A. niger and C. albicans fungi. Sapannone A inhibits LPS-induced inflammatory responses in vitro and in vivo, reducing nitric oxide (NO), interleukin-6 (IL-6), and prostaglandin E2 (PGE2; Item No. 14010) production in RAW264.7 cells as well as LPS-induced mortality in mice.{41702} It also attenuates airway inflammation and mucus hypersecretion via activation of the Nrf2 signaling pathway in a mouse model of ovalbumin-induced asthma.{41703}
Brand:CaymanSKU:23205 - 50 mgAvailable on backorder
Saquinavir is an HIV protease inhibitor (Kis = 0.12 and 1 and HIV-2 protease, respectively) that exhibits antiviral activity with low cytotoxicity.{25841,25842} When co-administered with 50 mg/kg ritonavir (Item No. 13872), the bioavailability of 20 mg/kg saquinavir has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.{25840}
Brand:CaymanSKU:9001893 - 10 mgAvailable on backorder
Saquinavir is an HIV protease inhibitor (Kis = 0.12 and 1 and HIV-2 protease, respectively) that exhibits antiviral activity with low cytotoxicity.{25841,25842} When co-administered with 50 mg/kg ritonavir (Item No. 13872), the bioavailability of 20 mg/kg saquinavir has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.{25840}
Brand:CaymanSKU:9001893 - 25 mgAvailable on backorder
Saquinavir is an HIV protease inhibitor (Kis = 0.12 and 1 and HIV-2 protease, respectively) that exhibits antiviral activity with low cytotoxicity.{25841,25842} When co-administered with 50 mg/kg ritonavir (Item No. 13872), the bioavailability of 20 mg/kg saquinavir has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.{25840}
Brand:CaymanSKU:9001893 - 5 mgAvailable on backorder
Saquinavir is an HIV protease inhibitor (Kis = 0.12 and 1 and HIV-2 protease, respectively) that exhibits antiviral activity with low cytotoxicity.{25841,25842} When co-administered with 50 mg/kg ritonavir (Item No. 13872), the bioavailability of 20 mg/kg saquinavir has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.{25840}
Brand:CaymanSKU:9001893 - 50 mgAvailable on backorder
Sauinavir-d9 is intended for use as an internal standard for the quantification of saquinavir (Item No. 9001893) by GC- or LC-MS. Saquinavir is an HIV protease inhibitor (Kis = 0.12 and 13872), the bioavailability of saquinavir (20 mg/kg) has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.{25840}
Brand:CaymanSKU:28906 - 1 mgAvailable on backorder
SAR131675 is an ATP-competitive inhibitor of VEGF receptor 3 (VEGFR3) with an IC50 value of 23 nM for the human recombinant receptor in a cell-free assay.{46458} It is selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively). SAR131675 inhibits survival of human lymphatic cells cultured with the VEGFR3-specific ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively). It decreases VEGF-C and VEGF-A-induced migration of human microvascular endothelial cells (HMVECs) when used at concentrations of 100 and 300 nM. SAR131675 (100 mg/kg) reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors. It also decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:28385 - 1 mgAvailable on backorder
SAR131675 is an ATP-competitive inhibitor of VEGF receptor 3 (VEGFR3) with an IC50 value of 23 nM for the human recombinant receptor in a cell-free assay.{46458} It is selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively). SAR131675 inhibits survival of human lymphatic cells cultured with the VEGFR3-specific ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively). It decreases VEGF-C and VEGF-A-induced migration of human microvascular endothelial cells (HMVECs) when used at concentrations of 100 and 300 nM. SAR131675 (100 mg/kg) reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors. It also decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:28385 - 10 mgAvailable on backorder
SAR131675 is an ATP-competitive inhibitor of VEGF receptor 3 (VEGFR3) with an IC50 value of 23 nM for the human recombinant receptor in a cell-free assay.{46458} It is selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively). SAR131675 inhibits survival of human lymphatic cells cultured with the VEGFR3-specific ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively). It decreases VEGF-C and VEGF-A-induced migration of human microvascular endothelial cells (HMVECs) when used at concentrations of 100 and 300 nM. SAR131675 (100 mg/kg) reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors. It also decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:28385 - 25 mgAvailable on backorder
SAR131675 is an ATP-competitive inhibitor of VEGF receptor 3 (VEGFR3) with an IC50 value of 23 nM for the human recombinant receptor in a cell-free assay.{46458} It is selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively). SAR131675 inhibits survival of human lymphatic cells cultured with the VEGFR3-specific ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively). It decreases VEGF-C and VEGF-A-induced migration of human microvascular endothelial cells (HMVECs) when used at concentrations of 100 and 300 nM. SAR131675 (100 mg/kg) reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors. It also decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:28385 - 5 mgAvailable on backorder
SAR20347 is an inhibitor of the JAK family kinases TYK2 and JAK1-3 (IC50s = 0.6, 23, 26, and 41 nM, respectively, in cell-free assays).{52137} It inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent STAT3 signaling in TF-1 cells (IC50 = 345 nM). SAR20347 (5 μM) inhibits IL-12-induced INF-γ production and reporter gene activity in peripheral blood mononuclear cells (PBMCs). In vivo, SAR20347 (60 mg/kg) inhibits the production of serum IFN-γ in mice. SAR20347 also reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22, and IFN-γ in a mouse model of psoriasis induced by imiquimod (Item No. 14956).
Brand:CaymanSKU:29248 - 1 mgAvailable on backorder
SAR20347 is an inhibitor of the JAK family kinases TYK2 and JAK1-3 (IC50s = 0.6, 23, 26, and 41 nM, respectively, in cell-free assays).{52137} It inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent STAT3 signaling in TF-1 cells (IC50 = 345 nM). SAR20347 (5 μM) inhibits IL-12-induced INF-γ production and reporter gene activity in peripheral blood mononuclear cells (PBMCs). In vivo, SAR20347 (60 mg/kg) inhibits the production of serum IFN-γ in mice. SAR20347 also reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22, and IFN-γ in a mouse model of psoriasis induced by imiquimod (Item No. 14956).
Brand:CaymanSKU:29248 - 10 mgAvailable on backorder
SAR20347 is an inhibitor of the JAK family kinases TYK2 and JAK1-3 (IC50s = 0.6, 23, 26, and 41 nM, respectively, in cell-free assays).{52137} It inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent STAT3 signaling in TF-1 cells (IC50 = 345 nM). SAR20347 (5 μM) inhibits IL-12-induced INF-γ production and reporter gene activity in peripheral blood mononuclear cells (PBMCs). In vivo, SAR20347 (60 mg/kg) inhibits the production of serum IFN-γ in mice. SAR20347 also reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22, and IFN-γ in a mouse model of psoriasis induced by imiquimod (Item No. 14956).
Brand:CaymanSKU:29248 - 25 mgAvailable on backorder
SAR20347 is an inhibitor of the JAK family kinases TYK2 and JAK1-3 (IC50s = 0.6, 23, 26, and 41 nM, respectively, in cell-free assays).{52137} It inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent STAT3 signaling in TF-1 cells (IC50 = 345 nM). SAR20347 (5 μM) inhibits IL-12-induced INF-γ production and reporter gene activity in peripheral blood mononuclear cells (PBMCs). In vivo, SAR20347 (60 mg/kg) inhibits the production of serum IFN-γ in mice. SAR20347 also reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22, and IFN-γ in a mouse model of psoriasis induced by imiquimod (Item No. 14956).
Brand:CaymanSKU:29248 - 5 mgAvailable on backorder
SAR260301 is an inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform β (IC50 = 52 nM).{34311} It is selective for p110β over other PI3K isoforms.{34311} SAR260301 demonstrates significant in vivo activity in a UACC-62 xenograft model in mice.{34311} It has synergistic antitumor activity when combined with the BRAF inhibitor vemurafenib (PLX4032; Item No. 10618) or the MEK inhibitor selumetinib (AZD 6244; Item No. 11599) in PTEN-deficient/BRAF-mutated human melanoma tumor models.{34310}
Brand:CaymanSKU:-Available on backorder
SAR260301 is an inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform β (IC50 = 52 nM).{34311} It is selective for p110β over other PI3K isoforms.{34311} SAR260301 demonstrates significant in vivo activity in a UACC-62 xenograft model in mice.{34311} It has synergistic antitumor activity when combined with the BRAF inhibitor vemurafenib (PLX4032; Item No. 10618) or the MEK inhibitor selumetinib (AZD 6244; Item No. 11599) in PTEN-deficient/BRAF-mutated human melanoma tumor models.{34310}
Brand:CaymanSKU:-Available on backorder
SAR260301 is an inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform β (IC50 = 52 nM).{34311} It is selective for p110β over other PI3K isoforms.{34311} SAR260301 demonstrates significant in vivo activity in a UACC-62 xenograft model in mice.{34311} It has synergistic antitumor activity when combined with the BRAF inhibitor vemurafenib (PLX4032; Item No. 10618) or the MEK inhibitor selumetinib (AZD 6244; Item No. 11599) in PTEN-deficient/BRAF-mutated human melanoma tumor models.{34310}
Brand:CaymanSKU:-Available on backorder
SAR260301 is an inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform β (IC50 = 52 nM).{34311} It is selective for p110β over other PI3K isoforms.{34311} SAR260301 demonstrates significant in vivo activity in a UACC-62 xenograft model in mice.{34311} It has synergistic antitumor activity when combined with the BRAF inhibitor vemurafenib (PLX4032; Item No. 10618) or the MEK inhibitor selumetinib (AZD 6244; Item No. 11599) in PTEN-deficient/BRAF-mutated human melanoma tumor models.{34310}
Brand:CaymanSKU:-Available on backorder
SAR405 is an inhibitor of the phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50 = 1.2 nM).{27429} It is without effect (IC50 > 10,000 nM) on other PI3K isoforms and mTOR. SAR405 alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation.{27429} SAR405 also synergizes with the mTOR inhibitor everolimus (Item No. 11597) in preventing the proliferation of renal tumor cell lines.{27429}
Brand:CaymanSKU:-Out of stock
SAR405 is an inhibitor of the phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50 = 1.2 nM).{27429} It is without effect (IC50 > 10,000 nM) on other PI3K isoforms and mTOR. SAR405 alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation.{27429} SAR405 also synergizes with the mTOR inhibitor everolimus (Item No. 11597) in preventing the proliferation of renal tumor cell lines.{27429}
Brand:CaymanSKU:-Out of stock
SAR405 is an inhibitor of the phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50 = 1.2 nM).{27429} It is without effect (IC50 > 10,000 nM) on other PI3K isoforms and mTOR. SAR405 alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation.{27429} SAR405 also synergizes with the mTOR inhibitor everolimus (Item No. 11597) in preventing the proliferation of renal tumor cell lines.{27429}
Brand:CaymanSKU:-Out of stock
SAR407899 is an ATP-competitive inhibitor of the Rho-associated kinases ROCK-I and ROCK-II (IC50s = 102 and 276 nM, respectively at a concentration of 40 μM ATP).{37269} SAR407899 is selective for ROCK over 79 other kinases at IC50 values up to 10 μM but had IC50 values ranging from 1 to 10 μM for RSK, PKB, PKCδ, and MSK-1. It is also selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 μM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50 values of 1.1 and 8.9 μM, respectively. In vitro, SAR407899 inhibits ROCK-mediated phosphorylation of myosin phosphatase (MYPT), thrombin-induced stress fiber formation, PDGF-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis. SAR407899 relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 μM).{37269},{37270} It inhibits constriction of rat and human arteries induced by endothelin-1 (ET-1; Emaxs = 24-83% of control).{37271}
Brand:CaymanSKU:21717 -Out of stock
SAR407899 is an ATP-competitive inhibitor of the Rho-associated kinases ROCK-I and ROCK-II (IC50s = 102 and 276 nM, respectively at a concentration of 40 μM ATP).{37269} SAR407899 is selective for ROCK over 79 other kinases at IC50 values up to 10 μM but had IC50 values ranging from 1 to 10 μM for RSK, PKB, PKCδ, and MSK-1. It is also selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 μM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50 values of 1.1 and 8.9 μM, respectively. In vitro, SAR407899 inhibits ROCK-mediated phosphorylation of myosin phosphatase (MYPT), thrombin-induced stress fiber formation, PDGF-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis. SAR407899 relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 μM).{37269},{37270} It inhibits constriction of rat and human arteries induced by endothelin-1 (ET-1; Emaxs = 24-83% of control).{37271}
Brand:CaymanSKU:21717 -Out of stock
SAR407899 is an ATP-competitive inhibitor of the Rho-associated kinases ROCK-I and ROCK-II (IC50s = 102 and 276 nM, respectively at a concentration of 40 μM ATP).{37269} SAR407899 is selective for ROCK over 79 other kinases at IC50 values up to 10 μM but had IC50 values ranging from 1 to 10 μM for RSK, PKB, PKCδ, and MSK-1. It is also selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 μM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50 values of 1.1 and 8.9 μM, respectively. In vitro, SAR407899 inhibits ROCK-mediated phosphorylation of myosin phosphatase (MYPT), thrombin-induced stress fiber formation, PDGF-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis. SAR407899 relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 μM).{37269},{37270} It inhibits constriction of rat and human arteries induced by endothelin-1 (ET-1; Emaxs = 24-83% of control).{37271}
Brand:CaymanSKU:21717 -Out of stock
SAR407899 is an ATP-competitive inhibitor of the Rho-associated kinases ROCK-I and ROCK-II (IC50s = 102 and 276 nM, respectively at a concentration of 40 μM ATP).{37269} SAR407899 is selective for ROCK over 79 other kinases at IC50 values up to 10 μM but had IC50 values ranging from 1 to 10 μM for RSK, PKB, PKCδ, and MSK-1. It is also selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 μM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50 values of 1.1 and 8.9 μM, respectively. In vitro, SAR407899 inhibits ROCK-mediated phosphorylation of myosin phosphatase (MYPT), thrombin-induced stress fiber formation, PDGF-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis. SAR407899 relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 μM).{37269},{37270} It inhibits constriction of rat and human arteries induced by endothelin-1 (ET-1; Emaxs = 24-83% of control).{37271}
Brand:CaymanSKU:21717 -Out of stock
SAR7334 is a transient receptor potential canonical 6 (TRPC6) channel blocker (IC50 = 7.9 nM).{47571} It is selective for TRPC6 over TRPC4 and TRPC5 (IC50s = 282 and 226 nM, respectively). SAR7334 (0.2-1 μM) blocks TRPC6-dependent hypoxia-induced vasoconstriction in isolated perfused and ventilated mouse lung. It also inhibits oxidative stress-induced apoptosis and increases autophagic flux in primary mouse renal proximal tubule cells.{47572}
Brand:CaymanSKU:28292 - 1 mgAvailable on backorder
SAR7334 is a transient receptor potential canonical 6 (TRPC6) channel blocker (IC50 = 7.9 nM).{47571} It is selective for TRPC6 over TRPC4 and TRPC5 (IC50s = 282 and 226 nM, respectively). SAR7334 (0.2-1 μM) blocks TRPC6-dependent hypoxia-induced vasoconstriction in isolated perfused and ventilated mouse lung. It also inhibits oxidative stress-induced apoptosis and increases autophagic flux in primary mouse renal proximal tubule cells.{47572}
Brand:CaymanSKU:28292 - 5 mgAvailable on backorder
SAR7334 is a transient receptor potential canonical 6 (TRPC6) channel blocker (IC50 = 7.9 nM).{47571} It is selective for TRPC6 over TRPC4 and TRPC5 (IC50s = 282 and 226 nM, respectively). SAR7334 (0.2-1 μM) blocks TRPC6-dependent hypoxia-induced vasoconstriction in isolated perfused and ventilated mouse lung. It also inhibits oxidative stress-induced apoptosis and increases autophagic flux in primary mouse renal proximal tubule cells.{47572}
Brand:CaymanSKU:28292 - 500 µgAvailable on backorder
Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively).{24595} It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases.{24595,24597,24594} Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival.{24595,24597,24598} Through its effects on c-Src, it reduces osteoclast bone resorption.{24597} Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.{24596}
Brand:CaymanSKU:11497 - 10 mgAvailable on backorder
Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively).{24595} It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases.{24595,24597,24594} Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival.{24595,24597,24598} Through its effects on c-Src, it reduces osteoclast bone resorption.{24597} Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.{24596}
Brand:CaymanSKU:11497 - 25 mgAvailable on backorder
Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively).{24595} It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases.{24595,24597,24594} Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival.{24595,24597,24598} Through its effects on c-Src, it reduces osteoclast bone resorption.{24597} Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.{24596}
Brand:CaymanSKU:11497 - 5 mgAvailable on backorder
Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively).{24595} It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases.{24595,24597,24594} Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival.{24595,24597,24598} Through its effects on c-Src, it reduces osteoclast bone resorption.{24597} Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.{24596}
Brand:CaymanSKU:11497 - 50 mgAvailable on backorder
Sarcosine is an intermediate in the biosynthesis of glycine from choline.{48332} It is a selective inhibitor of glycine transporter 1 (GlyT1) with IC50 values of 91 and greater than 1,000 µM for GlyT1 and GlyT2, respectively, in HEK293 cells expressing the human transporters.{48333} Sarcosine levels are increased in prostate cancer cell lines with an invasive phenotype compared with non-invasive cell lines.{48334} Sarcosine increases in a progressive fashion in prostate cancer with 0, 42, and 79% of benign, localized, and metastatic prostate tissue samples containing increased levels of sarcosine.
Brand:CaymanSKU:26799 - 100 gAvailable on backorder
Sarcosine is an intermediate in the biosynthesis of glycine from choline.{48332} It is a selective inhibitor of glycine transporter 1 (GlyT1) with IC50 values of 91 and greater than 1,000 µM for GlyT1 and GlyT2, respectively, in HEK293 cells expressing the human transporters.{48333} Sarcosine levels are increased in prostate cancer cell lines with an invasive phenotype compared with non-invasive cell lines.{48334} Sarcosine increases in a progressive fashion in prostate cancer with 0, 42, and 79% of benign, localized, and metastatic prostate tissue samples containing increased levels of sarcosine.
Brand:CaymanSKU:26799 - 250 gAvailable on backorder
Sarcosine is an intermediate in the biosynthesis of glycine from choline.{48332} It is a selective inhibitor of glycine transporter 1 (GlyT1) with IC50 values of 91 and greater than 1,000 µM for GlyT1 and GlyT2, respectively, in HEK293 cells expressing the human transporters.{48333} Sarcosine levels are increased in prostate cancer cell lines with an invasive phenotype compared with non-invasive cell lines.{48334} Sarcosine increases in a progressive fashion in prostate cancer with 0, 42, and 79% of benign, localized, and metastatic prostate tissue samples containing increased levels of sarcosine.
Brand:CaymanSKU:26799 - 50 gAvailable on backorder
Saroglitazar is a dual agonist of PPARα and PPARγ (EC50s = 0.65 and 3,000 pM, respectively, in a transactivation assay in HepG2 cells).{49145} It decreases serum triglyceride, free fatty acid, and glucose levels in a db/db mouse model of diabetes when administered at doses ranging from 0.01 to 3 mg/kg per day for 12 days. It increases insulin sensitivity in an oral glucose challenge when administered at a dose of 1 mg/kg in db/db mice, as well as decreases LDL levels in hApoB100/hCETP mice and in hamsters fed a high-fat high-cholesterol diet. Saroglitazar (10 µM) reverses palmitic acid-induced decreases in the expression of superoxide dismutase 1 (SOD1), SOD2, glutathione peroxidase (GPX), and catalase and increases in TNF-α, IL-1β, and IL-6 expression in HepG2 cells.{49146} It decreases hepatic inflammation and steatosis in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient high-fat diet when administered at a dose of 3 mg/kg and inhibits fibrosis in a mouse model of fibrosis induced by carbon tetrachloride.
Brand:CaymanSKU:27851 - 2.5 mgAvailable on backorder
Sarpogrelate is a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C (Kis = 3.02, 269, and 37.2 nM, respectively, for human recombinant receptors expressed in CHO-K1 cells).{39654} It is selective for 5-HT2 (Ki = 70.8 nM) over 5-HT1 (Ki = >26,000 nM), α1-, α2-, and β-adrenergic (Kis = 640-123,800 nM), and muscarinic receptors (Ki = >40,000 nM).{39658} In vitro, it inhibits aggregation of rat whole blood induced by collagen, 5-HT (Item No. 14332) with collagen, and 5-HT with ADP (Item No. 16778; IC50s = 57.7, 0.56, and 22.7 μM, respectively).{39655} In vivo, it inhibits leukocyte-endothelial interactions in the femoral artery induced by a high-fat high-fructose diet (HFFD) in mice when administered at a dose of 5 mg/kg per day.{39656} Sarpogrelate (5 mg/kg per day) decreases ventricular hypertrophy and infarct size in a rat model of myocardial infarction.{39657}
Brand:CaymanSKU:24194 - 10 mgAvailable on backorder
Sarpogrelate is a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C (Kis = 3.02, 269, and 37.2 nM, respectively, for human recombinant receptors expressed in CHO-K1 cells).{39654} It is selective for 5-HT2 (Ki = 70.8 nM) over 5-HT1 (Ki = >26,000 nM), α1-, α2-, and β-adrenergic (Kis = 640-123,800 nM), and muscarinic receptors (Ki = >40,000 nM).{39658} In vitro, it inhibits aggregation of rat whole blood induced by collagen, 5-HT (Item No. 14332) with collagen, and 5-HT with ADP (Item No. 16778; IC50s = 57.7, 0.56, and 22.7 μM, respectively).{39655} In vivo, it inhibits leukocyte-endothelial interactions in the femoral artery induced by a high-fat high-fructose diet (HFFD) in mice when administered at a dose of 5 mg/kg per day.{39656} Sarpogrelate (5 mg/kg per day) decreases ventricular hypertrophy and infarct size in a rat model of myocardial infarction.{39657}
Brand:CaymanSKU:24194 - 100 mgAvailable on backorder
Sarpogrelate is a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C (Kis = 3.02, 269, and 37.2 nM, respectively, for human recombinant receptors expressed in CHO-K1 cells).{39654} It is selective for 5-HT2 (Ki = 70.8 nM) over 5-HT1 (Ki = >26,000 nM), α1-, α2-, and β-adrenergic (Kis = 640-123,800 nM), and muscarinic receptors (Ki = >40,000 nM).{39658} In vitro, it inhibits aggregation of rat whole blood induced by collagen, 5-HT (Item No. 14332) with collagen, and 5-HT with ADP (Item No. 16778; IC50s = 57.7, 0.56, and 22.7 μM, respectively).{39655} In vivo, it inhibits leukocyte-endothelial interactions in the femoral artery induced by a high-fat high-fructose diet (HFFD) in mice when administered at a dose of 5 mg/kg per day.{39656} Sarpogrelate (5 mg/kg per day) decreases ventricular hypertrophy and infarct size in a rat model of myocardial infarction.{39657}
Brand:CaymanSKU:24194 - 250 mgAvailable on backorder
Sarpogrelate is a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C (Kis = 3.02, 269, and 37.2 nM, respectively, for human recombinant receptors expressed in CHO-K1 cells).{39654} It is selective for 5-HT2 (Ki = 70.8 nM) over 5-HT1 (Ki = >26,000 nM), α1-, α2-, and β-adrenergic (Kis = 640-123,800 nM), and muscarinic receptors (Ki = >40,000 nM).{39658} In vitro, it inhibits aggregation of rat whole blood induced by collagen, 5-HT (Item No. 14332) with collagen, and 5-HT with ADP (Item No. 16778; IC50s = 57.7, 0.56, and 22.7 μM, respectively).{39655} In vivo, it inhibits leukocyte-endothelial interactions in the femoral artery induced by a high-fat high-fructose diet (HFFD) in mice when administered at a dose of 5 mg/kg per day.{39656} Sarpogrelate (5 mg/kg per day) decreases ventricular hypertrophy and infarct size in a rat model of myocardial infarction.{39657}
Brand:CaymanSKU:24194 - 50 mgAvailable on backorder
Immunogen: Recombinant SARS-CoV nucleocapsid protein • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Application: ELISA
Brand:CaymanSKU:31430- 100 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein is a viral protein encoded by the N gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The SARS-CoV nucleocapsid protein has a greater than 90% similarity to the SARS-CoV-2 nucleocapsid protein, and SARS-CoV-2 contains 27 T cell epitopes that are identical to SARS-CoV T cell epitopes.{49555} The SARS-CoV nucleocapsid protein packages the viral RNA into a helical ribonucleoprotein complex (RNP) that is a template for viral replication.{53460} It is integral for viral self-assembly and involved with regulation of the cell cycle. SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Nucleocapsid Protein Polyclonal Antibody can be used for ELISA.
Brand:CaymanSKU:31430 - 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV nucleocapsid protein • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Application: ELISA
Brand:CaymanSKU:31430- 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV nucleocapsid protein • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Application: ELISA
Brand:CaymanSKU:31430- 200 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein is a viral protein encoded by the N gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The SARS-CoV nucleocapsid protein has a greater than 90% similarity to the SARS-CoV-2 nucleocapsid protein, and SARS-CoV-2 contains 27 T cell epitopes that are identical to SARS-CoV T cell epitopes.{49555} The SARS-CoV nucleocapsid protein packages the viral RNA into a helical ribonucleoprotein complex (RNP) that is a template for viral replication.{53460} It is integral for viral self-assembly and involved with regulation of the cell cycle. SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Nucleocapsid Protein Polyclonal Antibody can be used for ELISA.
Brand:CaymanSKU:31430 - 200 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV nucleocapsid protein • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Application: ELISA
Brand:CaymanSKU:31430- 200 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Mouse • Species Reactivity: (+) SARS-CoV; (-) SARS-CoV-2, MERS-CoV, HCoV-HKU1 (Isolate N1), HCoV-HKU1 (Isolate N5), HCoV-229E, HCoV-OC43 • Applications: ELISA
Brand:CaymanSKU:31431- 100 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46767,46768,49561,49525} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Surface Glycoprotein S1 Subunit Monoclonal Antibody can be used for ELISA. The antibody recognizes the S1 subunit to detect the SARS-CoV surface glycoprotein.
Brand:CaymanSKU:31431 - 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Mouse • Species Reactivity: (+) SARS-CoV; (-) SARS-CoV-2, MERS-CoV, HCoV-HKU1 (Isolate N1), HCoV-HKU1 (Isolate N5), HCoV-229E, HCoV-OC43 • Applications: ELISA
Brand:CaymanSKU:31431- 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Mouse • Species Reactivity: (+) SARS-CoV; (-) SARS-CoV-2, MERS-CoV, HCoV-HKU1 (Isolate N1), HCoV-HKU1 (Isolate N5), HCoV-229E, HCoV-OC43 • Applications: ELISA
Brand:CaymanSKU:31431- 50 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46767,46768,49561,49525} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Surface Glycoprotein S1 Subunit Monoclonal Antibody can be used for ELISA. The antibody recognizes the S1 subunit to detect the SARS-CoV surface glycoprotein.
Brand:CaymanSKU:31431 - 50 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Mouse • Species Reactivity: (+) SARS-CoV; (-) SARS-CoV-2, MERS-CoV, HCoV-HKU1 (Isolate N1), HCoV-HKU1 (Isolate N5), HCoV-229E, HCoV-OC43 • Applications: ELISA
Brand:CaymanSKU:31431- 50 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 100 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46768,46767,49525,49561} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Surface Glycoprotein S1 Subunit Polyclonal Antibody can be used for ELISA and Western blot (WB; reducing conditions) applications.
Brand:CaymanSKU:31433 - 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 100 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 200 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46768,46767,49525,49561} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Surface Glycoprotein S1 Subunit Polyclonal Antibody can be used for ELISA and Western blot (WB; reducing conditions) applications.
Brand:CaymanSKU:31433 - 200 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 200 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 50 µl Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46768,46767,49525,49561} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Surface Glycoprotein S1 Subunit Polyclonal Antibody can be used for ELISA and Western blot (WB; reducing conditions) applications.
Brand:CaymanSKU:31433 - 50 µlAvailable on backorder
Immunogen: Recombinant SARS-CoV surface glycoprotein S1 subunit • Host: Rabbit • Species Reactivity: (+) SARS-CoV • Applications: ELISA and WB (reducing conditions)
Brand:CaymanSKU:31433- 50 µlAvailable on backorder
A set of SARS-CoV-2 neutralizing antibody human plasma controls containing negative control plasma, as well as positive control plasma spiked with low, mid, and high levels of recombinant human anti-SARS-CoV-2 neutralizing IgG antibody
Brand:CaymanSKU:502080- 1 ea Cayman’s SARS-CoV-2 Neutralizing Antibody Human Plasma Control Set contains human plasma collected prior to the SARS-CoV-2 pandemic that has been spiked at low, mid, or high levels with a recombinant human anti-SARS-CoV-2 neutralizing IgG antibody. A negative control, free of neutralizing antibody, is also included. The levels of neutralizing antibody to be added to each control were determined by screening numerous positive and negative samples using Cayman’s SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (Item No. 502070). The amount of neutralizing antibody spiked into the controls was designed to be representative of the range of antibody levels found in a typical sample set.
Brand:CaymanSKU:502080 - 1 eaAvailable on backorder